FH is more common than type 1 diabetes.2
It affects 1 in 250 individuals worldwide (approximately 1.3 million individuals in the United States).3,4,5
90-99% of individuals with FH are not accurately diagnosed in the US.3
If not identified and appropriately treated from an early age, individuals with FH have a 20-fold increased lifetime and population-based risk of heart disease.6
Data has shown that untreated men with FH have a 50% chance of a myocardial infarction by age 50 and women have a 30% chance by age 60.7
However, with proactive treatment, an affected individual’s lifetime risk of cardiovascular disease approaches the risk in the general population.8
- The FH Foundation built a machine-learning algorithm based on structured and unstructured data is implementing it to identify individuals with probable FH within EHRs, large-scale lab results, and claims databases.
- A heat map showing the geographic distribution of individuals with probable FH at the healthcare provider level is being generated.
- Healthcare providers with concentrations of individuals with probable FH have the opportunity to learn about patients with probable FH in their practice. Data providers share the identified patient information with the HCP if requested explicitly by the HCP. Additionally, the FH Foundation is establishing patient Digital Engagement Strategies to promote FH awareness, encourage screening, and provide the necessary tools and resources.
HOW FIND FH® WORKS
WHEN AN FH DIAGNOSIS SHOULD BE CONSIDERED
WHY FH SHOULD BE DIAGNOSED
HOW THE FH FOUNDATION CAN HELP YOUR PRACTICE
FAMILY CASCADE SCREENING
- Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5:S9-17
- Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Chapter 1: Epidemiology of Type 1 Diabetes. Endocrinol Metab Clin North Am. 2010 September ; 39(3): 481–497. doi:10.1016/j.ecl.2010.05.011.
- Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European heart journal 2013.
- Sjouke B, Kusters DM, Kindt I, Besseling J, Defesche JC, Sijbrands EJ, Roeters van Lennep JE, Stalenhoef AF, Wiegman A, de Graaf J, Fouchier SW, Kastelein JJ, Hovingh G. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015;36:560–565.
- Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK, Livingston M, Mata P, Parhofer KG, Raal FJ, Santos RD, Sijbrands EJ, Simpson WG, Sullivan DR, Susekov AV, Tomlinson B, Wiegman A, Yamashita S, Kastelein JJ.
- Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5:S1-8.Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. Int J Cardiol 2014;171:309–325.
- Marks D, Thorogood M, Neil HA et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003;168:1-14
- Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. Bmj 2008;337:a2423